Summary & Overview
HCPCS J9049: Bortezomib (Hospira) Injection, 0.1 mg
HCPCS Level II code J9049 denotes a 0.1 mg unit of bortezomib (Hospira), identified as not therapeutically equivalent to J9041. Bortezomib is an injectable proteasome inhibitor used in oncology care; accurate coding ensures proper drug identification, billing transparency, and alignment with payer policies nationwide. This code matters nationally because biologics and branded biosimilars have distinct coding that affects coverage determinations, pharmacy billing, and reimbursement workflows across providers and payers.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for J9049, expected sites of service, and the typical service line for chemotherapy drug administration. The publication outlines benchmarking and payer coverage themes, common modifier usage patterns (listed separately), and operational considerations for drug-specific HCPCS reporting.
This summary equips billing, revenue cycle, and clinical leadership with the essentials: what J9049 represents, why specific HCPCS identification matters for antineoplastic agents, and what to expect when coordinating claims with major national payers. Data not available in the input for specific payer rates, taxonomies, and ICD-10 pairings are noted elsewhere in the full publication.
Billing Code Overview
HCPCS Level II code J9049 represents an injection of bortezomib (Hospira), specified as not therapeutically equivalent to J9041, dosed per 0.1 mg. This code is used to report the actual drug product when administered parenterally.
-
Service type: Injectable chemotherapy/antineoplastic agent administration
-
Typical site of service: Hospital outpatient department, infusion center, or physician office infusion suite
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with multiple myeloma or mantle cell lymphoma receiving parenteral chemotherapy in an outpatient infusion center or hospital outpatient department. The prescription is for J9049 (bortezomib, 0.1 mg, Hospira formulation) administered via subcutaneous or intravenous injection according to oncology protocols. Clinical workflow: medication order and verification by oncologist and pharmacist; pre‑treatment assessment including vital signs, neuropathy evaluation, and review of prior labs (CBC, CMP); placement of an IV or use of subcutaneous injection site; administration by an oncology nurse with appropriate aseptic technique; post‑administration monitoring for infusion reactions, hypotension, bleeding risk, and neuropathy progression; documentation of dose (mg), lot number, route (IV or SQ), and any immediate adverse events; billing with J9049 per 0.1 mg units and appropriate modifier(s) reflecting payer or service circumstances.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard use when no adjustment applies |
23 |